| pubmed-article:9155703 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9155703 | lifeskim:mentions | umls-concept:C0031511 | lld:lifeskim |
| pubmed-article:9155703 | lifeskim:mentions | umls-concept:C0597879 | lld:lifeskim |
| pubmed-article:9155703 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9155703 | pubmed:dateCreated | 1997-5-29 | lld:pubmed |
| pubmed-article:9155703 | pubmed:abstractText | The aim was to evaluate Leu-M1 immunoreactivity as a prognostic factor in phaeochromocytoma. Anti-Leu-M1 monoclonal antibodies were used to determine the Leu-M1 immunoreactivity in 17 histologically confirmed phaeochromocytomas from 15 patients, using an avidin-biotin technique. Ten patients had a sporadic phaeochromocytoma, and five had multiple endocrine neoplasia type 2A (MEN 2A). Malignancy was diagnosed in three patients by the presence of metastases. Leu-M1 immunoreactivity was shown in 12 (70.5%) phaeochromocytomas. Three patterns of arrangement were observed: isolated (scattered positive cells) (n = 3); focal (aggregates of positive cells) (n = 5), and diffuse patterns (dispersed positive cells) (n = 4). Two cases of malignant phaeochromocytoma were positive (one focal and one isolated pattern). All cases of MEN 2A showed immunoreactivity, although no characteristic pattern was prevalent. A diffuse pattern was observed in all phaeochromocytomas longer than 7 cm. In conclusion, Leu-M1 expression is frequent in phaeochromocytoma. However, Leu-M1 immunoreactivity seems to be useless in predicting malignant behaviour and to be influenced mainly by tumour size. | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9155703 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9155703 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9155703 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9155703 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9155703 | pubmed:issn | 0021-9746 | lld:pubmed |
| pubmed-article:9155703 | pubmed:author | pubmed-author:VidalM TMT | lld:pubmed |
| pubmed-article:9155703 | pubmed:author | pubmed-author:GarcíaAA | lld:pubmed |
| pubmed-article:9155703 | pubmed:author | pubmed-author:SimóRR | lld:pubmed |
| pubmed-article:9155703 | pubmed:author | pubmed-author:MasmiquelLL | lld:pubmed |
| pubmed-article:9155703 | pubmed:author | pubmed-author:de TorresII | lld:pubmed |
| pubmed-article:9155703 | pubmed:author | pubmed-author:Castro-FornsM... | lld:pubmed |
| pubmed-article:9155703 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9155703 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:9155703 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9155703 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9155703 | pubmed:pagination | 168-70 | lld:pubmed |
| pubmed-article:9155703 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:meshHeading | pubmed-meshheading:9155703-... | lld:pubmed |
| pubmed-article:9155703 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9155703 | pubmed:articleTitle | Leu-M1 immunoreactivity and phaeochromocytoma. | lld:pubmed |
| pubmed-article:9155703 | pubmed:affiliation | Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. | lld:pubmed |
| pubmed-article:9155703 | pubmed:publicationType | Journal Article | lld:pubmed |
